

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	09/927,341
				Filing Date	August 13, 2001
				First Named Inventor	Barry Forman, et al.
				Group Art Unit	<del>To be assigned</del> 1642
				Examiner Name	<del>To be assigned</del> A. HOLLERAN
Sheet	1	of	5	Attorney Docket Number	1954-352

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
Art		5,217,867		Evans et al.	Jun. 8, 1993
Art		5,571,696		Evans et al.	Nov. 5, 1996
Art		5,710,004		Evans et al.	Jan. 20, 1998
Art		5,736,157		Williams	Apr. 7, 1998
Art		5,906,920		Evans et al.	May 25, 1999
Art		5,702,914		Evans et al.	Dec. 30, 1997
Art		5,071,773		Evans et al.	Dec. 10, 1991

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
Art			WO 97/35195		The Salk Institute for Biological Studies	Sept. 25, 1997	
Art			WO 94/18346		The Board of Regents of the University of Texas System	Aug. 18, 1994	

Examiner Signature	<i>A. Holleran</i>	Date Considered	1/8/2004
-----------------------	--------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	09/927,341
				Filing Date	August 13, 2001
				First Named Inventor	Barry Forman, et al.
				Group Art Unit	To be assigned 1642
				Examiner Name	To be assigned A. HOLLERAN
Sheet	2	of	5	Attorney Docket Number	1954-352
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
Art		Blumberg, B., et al., "SXR, a novel steroid and xenobiotic-sensing nuclear receptor," <u>Genes &amp; Development</u> , Vol. 12, pp. 3195-3205, 1998.			
Art		Xie, W., et al., "Humanized xenobiotic response in mice expressing nuclear receptor SXR," <u>Nature</u> , Vol. 406, pp. 435-439, July 27, 2000.			
Art		Bertilsson, G., et al., "Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95, pp. 12208-12213, October 1998.			
Art		Forman, B.M., et al., "Unique Response Pathways Are Established by Allosteric Interactions among Nuclear Hormone Receptors," <u>Cell</u> , Vol. 81, pp. 541-550, May 19, 1995.			
Art		Lehmann, J.M., et al., "The Human Orphan Nuclear Receptor PXR is Activated by Compounds That Regulate CYP3A4 Gene Expression and Cause Drug Interactions," <u>J. Clin. Invest.</u> , Vol. 102, No. 5, pp. 1016-1023, September 1998.			
Art		Shen, D.W., et al., "Human Multidrug-Resistant Cell Lines: Increased <i>mdr1</i> Expression Can Precede Gene Amplification," <u>Science</u> , Vol. 232, pp. 643-645, May 2, 1986.			
Art		Forman, B., et al., "15-Deoxy- $\Delta^{12,14}$ -Prostaglandin J2 Is a Ligand for the Adipocyte Determination Factor PPAR $\gamma$ ," <u>Cell</u> , Vol. 83, pp. 803-812, December 1, 1995.			
Art		Synold, et al., "The Orphan Nuclear Receptor SXR Coordinately regulates Drug Metabolism and Efflux," <u>Nature Medicine</u> , Vol. 7, No. 5, pp 584-590, May 2001.			
Examiner Signature	Anne C. Holleran			Date Considered	1/8/2004


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.


<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	09/927,341
				Filing Date	August 13, 2001
				First Named Inventor	Barry Forman, et al.
				Group Art Unit	To be assigned 1642
				Examiner Name	To be assigned A. Holleran
Sheet	3	of	5	Attorney Docket Number	1954-352
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
AC/H		Kliwer, S.A., et al., "An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway," <u>Cell</u> , Vol. 92, 73-82, January 9, 1998.			
AC/H		Apfel, R., et al., "A Novel Orphan Receptor Specific for a Subset of Thyroid Hormone-Responsive Elements and Its Interaction with the Retinoid/Thyroid Hormone Receptor Subfamily," <u>Molecular and Cellular Biology</u> , Vol. 14, No. 10, pp. 7025-7035, October 1994.			
AC/H		Hong, H., et al., "GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, pp. 4948-4952, May 1996.			
AC/H		Brown, M.S., et al., "The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor," <u>Cell</u> , Vol. 89, pp. 331-340, May 2, 1997.			
AC/H		Gottesman, M.M., et al., "Biochemistry of Multidrug Resistance Mediated by the Multidrug Transporter," <u>Annu. Rev. Biochem.</u> , Vol. 62, pp. 385-427, 1993.			
AC/H		Boehm, M.F., et al., "Design and Synthesis of Potent Retinoid X Receptor Selective Ligands That Induce Apoptosis in Leukemia Cells," <u>J. Med. Chem.</u> , Vol. 38, pp. 3146-3155, 1995.			
AC/H		Noonan, K.E., et al., "Quantitative analysis of <i>MDR1</i> (multidrug resistance) gene expression in human tumors by polymerase chain reaction," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 87, pp. 7160-7164, September 1990.			
Examiner Signature	Anne C. Holleran			Date Considered	1/8/2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	09/927,341
				Filing Date	August 13, 2001
				First Named Inventor	Barry Forman, et al.
				Group Art Unit	To be assigned 1642
				Examiner Name	To be assigned A. HOLLERAN
Sheet	4	of	5	Attorney Docket Number	1954-352
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initialed	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
		Forman, B.M, et al., "The orphan nuclear receptor LXR $\alpha$ is positively and negatively regulated by distinct products of mevalonate metabolism," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 94, pp. 10588-10593, September 1997.			
		Glass, C.K., et al., "Nuclear receptor coactivators," <u>Curr. Opin. Cell Bio.</u> , Vol. 9, pp. 222-232, 1997.			
A.H.		Mangelsdorf, D.J., et al., "The RXR Heterodimers and Orphan Receptors," <u>Cell</u> , Vol. 83, pp. 841-850, December 15, 1995.			
A.H.		Janowski et al., "An oxysterol signalling pathway mediated by the nuclear receptor LXR $\alpha$ ," <u>Nature</u> , 383:728-731 (1996).			
A.H.		Kenneth L. Rinehart, "Antitumor Compounds From Tunicates", <u>Med. Res. Rev.</u> , Vol. 20, pp 1-27, 2000.			
A.H.		Izbicka, et al., "In Vitro Antitumor Activity of the Novel Marine Agent, Ecteinascidin-743 (ET-743, NSC-648766) Against Human Tumors Explanted From Patients", <u>Annals of Oncology</u> , Vol. 9, pp 981-987, 1998.			
A.H.		Hendriks, et al., "High Antitumour Activity of ET743 Against Human Tumour Xenografts from Melanoma, Non-Small-Cell Lung and Ovarian Cancer, <u>Annals of Oncology</u> , Vol. 10, pp 1233-1240, 1999.			
A.H.		Zewail-Foote, et al., "Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA Toward the Major Groove", <u>Journal Of Medicinal Chemistry</u> , Vol. 42, No. 14, pp 2493-2497, 1999.			
A.H.		Pommier, et al., "DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, A Potent...", <u>Biochemistry</u> , 35, pp 13303-13309, 1996.			
A.H.		Takebayashi, et al., "Poisoning of Human DNA Topoisomerase I...", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 7196-7201, June 1999.			
A.H.		Bonfanti, et al., "Effect of ecteinascidin-743 on the Interaction...", <u>Anti-Cancer Drug Design</u> , 14, pp 179-186, 1999.			
A.H.		Jin, et al., "Ecteinascidin 743, A Transcriptin-targeted Chemotherapeutic...", <u>PNAS</u> , Vol. 97, No. 12, pp. 6775-6779, June 6, 2000.			
A.H.		Minuzzo, et al., "Interference of Transcriptional Activation by the Antineoplastic...", <u>PNAS</u> , Vol. 97, pp. 6780-6784, June 6, 2000.			
A.H.		Forman, et al., "Androstane metabolites bind to and deactivate the nuclear receptor CAR- $\beta$ ", <u>Nature</u> , Vol. 395, pp 612-615, October 8, 1998.			
A.H.		Pallis, et al., "P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic...", <u>Blood</u> , Vol. 95, No. 9, pp 2897-2904, May 1, 2000.			

*Anne C. Holleran 1/8/2004*

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Complete if Known</i>		
				Application Number	09/927,341	
				Filing Date	August 13, 2001	
				First Named Inventor	Barry Forman, et al.	
				Group Art Unit	<del>To be assigned</del> 1642	
				Examiner Name	<del>To be assigned</del> A. HOLLERAN	
Sheet	5	of	5	Attorney Docket Number	1954-352	
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>	
		Kliwer, et al., "Orphan Nuclear Receptors: Shifting Endocrinology into Reverse", <u>Science</u> , Vol. 284, pp 757-760, April 30, 1999.				
		Forman, et al., "Hypolipidemic drugs, polyunsaturated fatty acids,...", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 94, pp 4312-4317, April, 1997.				
		Wang, et al., "Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR", <u>Molecular Cell</u> , Vol. 3, pp 543-553, May, 1999.				
	A.H.		Wacher, et al., "Overlapping Substrate Specificities and Tissue Distribution...", <u>Molecular Carcinogenesis</u> , 13:, pp 129-134, 1995.			
	A.H.		Schuetz, et al., "Modulators and Substrates of P-glycoprotein and Cytochrome...", <u>Molecular Pharmacology</u> , 49:, pp 311-318, 1996			
Examiner Signature	Anne L. Holleran			Date Considered	1/8/2004	

\*EXAMINER: Initial if referred to, considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Complete if Known**

Application Number 09/927,341

<b>Filing Date</b>	<b>August 13, 2001</b>
--------------------	------------------------

First Named Inventor	Barry FORMAN et al.
----------------------	---------------------

Group Art Unit	1642
----------------	------

**Examiner Name** Anne L. Holleran

Sheet

1

of

1

Attorney Docket Number | 1954-352

## U.S. PATENT DOCUMENTS

[illegible]


## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
ACH		PCT	WO 99/35246 <i>&amp; Corrected version</i>	A1	The Salk Institute for Biological Studies	07/15/1999	
ACH		PCT	WO 99/61622	A1	The University of Sydney	12/02/1999	
ACH		PCT	WO 01/72837	A2/A3	City of Hope	10/04/2001	
Examiner Signature	Anne L. Hellman				Date Considered	1/8/2004	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB Indicates that only an English language abstract is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT



Complete if Known

Application Number 09/927,341  
Filing Date August 13, 2001  
First Named Inventor Barry FORMAN et al.  
Group Art Unit 1642  
Examiner Name Anne L. Holleran  
Attorney Docket Number 1954-352

RECEIVED  
MAY 14 2003  
TECH CENTER 1600/2800

Sheet 1 of 1

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
AK		Jin, Shengkan, et al., "Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation," Proceedings of the National Academy of Sciences of the United States 97(12):6775-6779, June 6, 2000.	
AK		Synold, Timothy, W., et al., "The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux," Nature Medicine 7(5):584-590, May 2001.	
Examiner Signature	Anne L. Holleran		Date Considered 1/8/2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not consider d. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.